Dr. James Wilson -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. James Wilson, a Oncology physician based in City, AZ. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. James Wilson has received $9,567.92 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. James Wilson
- Medical Specialty: Oncology
- Practice Location: City, AZ, Arizona
- NPI Number: 1174617536
- Transparency Score: 50/100
- Payment Records Span: 2025-05-18 to 2025-05-18
Payment Summary
Dr. James Wilson has received a total of $9,567.92 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $9,567.92 per transaction.
- Total Payments Received: $9,567.92
- Number of Transactions: 1
- Average Payment: $9,567.92
- Transparency Score: 50/100 -- This score reflects the overall payment profile relative to peers in Oncology. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
- Drugs/Devices Referenced: 1 distinct products
Payment Breakdown by Category
The following table shows how Dr. James Wilson's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Consulting Fees | $9,567.92 | Advisory board participation, clinical consulting, and expert opinion services |
The largest payment category for Dr. James Wilson is Consulting Fees, accounting for 100% ($9,567.92) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. James Wilson. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| AbbVie Inc | $9,567.92 | 1 |
Dr. James Wilson has a financial relationship with AbbVie Inc, receiving $9,567.92 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
Drugs and Medical Devices Referenced in Payments
The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. James Wilson. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.
- Farxiga -- Referenced in payment records from pharmaceutical companies to Dr. James Wilson
The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. James Wilson's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Dr. James Wilson, an Oncologist in City, AZ, has a pharmaceutical payment profile characterized by a single, notable transaction. With a total of $9,567.92 from pharmaceutical companies, this amount is relatively low when compared to the broader landscape of Oncology, where average payments can be significantly higher due to the complex and research-intensive nature of cancer treatment. The data indicates that this entire sum originates from AbbVie Inc., a major biopharmaceutical company. This singular relationship suggests a focused engagement, potentially for consulting services, as indicated by the payment details. The payment is listed for consulting on May 18, 2025, which is in the future, suggesting this might be a projected or reported payment rather than a historical one. This pattern, with one payment from one company, does not immediately suggest routine professional activity across a wide range of pharmaceutical interactions. Instead, it points to a specific engagement. In the context of patient care, it's important to understand that pharmaceutical companies engage with physicians for various reasons, including sharing information about new treatments, gathering insights on drug efficacy and patient needs, and funding research. While such relationships can facilitate the dissemination of medical knowledge and advance research, they also raise questions about potential influence on prescribing habits. Patients should be aware that while these payments are disclosed, they do not automatically equate to biased medical decisions. However, understanding the nature and extent of these relationships can empower patients to have more informed discussions with their healthcare providers about treatment options and potential conflicts of interest. Dr. Wilson's profile, with its limited and specific payment, offers a clear, albeit narrow, view of his interactions with the pharmaceutical industry.
Patient Guidance: Questions to Ask Your Doctor
If Dr. James Wilson is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
When considering your doctor's relationship with pharmaceutical companies, it's helpful to approach the information with a balanced perspective. These relationships are common and can be beneficial, facilitating the flow of information about new treatments and research. However, transparency is key to maintaining trust. At your next appointment, consider asking your doctor about their relationships with drug companies, especially if they are prescribing a new medication. You might ask, "Are there any financial relationships you have with the companies whose medications you prescribe?" or "Are there alternative treatments available, and what are the pros and cons of each?" Red flags might include a doctor who seems overly enthusiastic about a specific drug without a clear clinical rationale, or who consistently prescribes expensive brand-name drugs when equally effective generics are available, especially if they have significant financial ties to that drug's manufacturer. It's important to remember that a financial relationship doesn't automatically mean a doctor's judgment is compromised. Many physicians maintain ethical standards and prioritize patient well-being. However, being informed allows you to have more productive conversations and make shared decisions about your care. You can verify payment data yourself through the CMS Open Payments database.
Peer Comparison: How Dr. James Wilson Compares to Other Oncology Physicians
Oncologists often engage in more extensive relationships with pharmaceutical companies due to the nature of cancer research and drug development. While average payment ranges can vary widely, many oncologists receive multiple payments for consulting, speaking, and research. Dr. Wilson's total payment of $9,567.92 from a single transaction is considerably lower than the typical volume seen in this specialty, suggesting a less frequent or less involved engagement with pharmaceutical entities compared to many of his peers.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. James Wilson in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| AbbVie Inc | $9,567.92 | consulting | Farxiga | 2025-05-18 | Not Assessed |
Frequently Asked Questions About Dr. James Wilson's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
Is Dr. James Wilson taking too much pharma money?
Dr. Wilson's total pharmaceutical payments are $9,567.92, stemming from a single consulting payment from AbbVie Inc. This amount is relatively low compared to the average for Oncologists, who often have more extensive relationships due to research and drug development in the field. While any payment warrants attention, this singular, specific transaction does not suggest an excessive reliance on pharmaceutical funding based on the provided data alone. It indicates a focused engagement rather than broad financial ties.
What pharma companies pay Dr. James Wilson?
Dr. James Wilson receives payments exclusively from AbbVie Inc. The total amount from this company is $9,567.92. This represents the entirety of his disclosed pharmaceutical payments.
Should I switch doctors because of pharma payments?
Switching doctors solely based on pharmaceutical payments is a significant decision. Dr. Wilson's profile shows a single payment, which is less extensive than many in his field. Consider the overall quality of care, communication, and trust you have with your doctor. If you have concerns about potential conflicts of interest, discuss them openly. If the payments are substantial and from companies whose drugs you are prescribed, and you feel uncomfortable or lack trust, then exploring other options might be warranted. However, a nuanced view considering the specific context is crucial.
What kinds of payments does this doctor receive?
Dr. Wilson's disclosed payments consist solely of consulting fees. The total amount is $9,567.92, attributed to consulting with AbbVie Inc. There are no reported payments for speaking engagements, meals, travel, research, or ownership interests.
How do these payments compare to other Oncology?
Oncology is a field with significant pharmaceutical involvement. While specific averages vary, many oncologists receive multiple payments for various activities like consulting, research, and speaking. Dr. Wilson's single payment of $9,567.92 is considerably lower than the typical volume and frequency of payments observed among his peers in Oncology, suggesting a more limited engagement with the industry.
Do pharma payments affect prescribing quality?
Research suggests that even small payments can influence physician prescribing habits, potentially leading to increased use of the paying company's drugs. However, the extent of this influence is debated, and many physicians maintain ethical practices. It's crucial to consider the totality of a doctor's practice, their communication, and your personal trust, rather than relying solely on payment data. Open discussion about treatment options is key.
How can I verify this payment data?
You can verify this payment data directly through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. This official government website allows you to search for physicians and teaching hospitals and view their reported financial relationships with the pharmaceutical and medical device industries. You can access it by searching for 'CMS Open Payments' online.
Understanding This Doctor Payment Report
This transparency report for Dr. James Wilson is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Oncology physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. James Wilson's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. James Wilson and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Oncology Specialty Payment Data -- See payment patterns for all oncology physicians
- Arizona Physician Payments -- Browse pharmaceutical payments to physicians in Arizona
- Oncology Physicians in Arizona -- Compare Dr. James Wilson to peers in the same state and specialty
- AbbVie Inc Payment Profile -- View all payments made by Dr. James Wilson's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. James Wilson's NPI (1174617536) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.